‹ ›
MYP_035309
← PREVIOUS NEXT → BACK
Basic Information
IBP02V3
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor cross
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
36 amino acids
C173H294N48O61
Standard
Sequence
EISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL
Physicochemical Analysis
4022.47 Da
4.25
-4.15
-4.33
-0.1153
-0.18
0.70
-0.00
47.93
138.06
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1819.18
-18.85
59.0
57.0
144.0
282.0
0.0
42.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0210151 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
PEG8-K(Chol)
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells
0.0758±0.0099 μM
IC50
PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0222530 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG8-K(Chol)
PEG8-K(Chol)
Bio-Activity Profile
Antiviral Anti-HCoV-NL63 Fusion inhibition
HCoV-NL63 | Huh-7 cells
0.0758±0.0099 μM
IC50
Mammalian: 1 h; Yeast: 30 min; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0228337 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
PEG8-K(Chol)
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
inhibition of pseudovirus infection in 293T/ACE2 cells
0.0402 μM
IC50
PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0258718 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG8-K(Chol)
PEG8-K(Chol)
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 | protein-mediated cell; -cell
0.0004±0.00002 μM
IC50
Mammalian: 1 h; Yeast: 30 min; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0269654 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG8-K(Chol)
PEG8-K(Chol)
Bio-Activity Profile
Antiviral Anti-SARS-CoV Fusion inhibition
SARS-CoV | Huh-7 cells
0.048±0.0058 μM
IC50
Mammalian: 1 h; Yeast: 30 min; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
FIRST PREV 1 2 3 4 5 NEXT LAST
Showing 5 records on this page · Page 3 of 5